Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests
Identifieur interne : 000024 ( PascalFrancis/Corpus ); précédent : 000023; suivant : 000025Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests
Auteurs : Kwok-Hung Chan ; Jasper Fuk-Woo Chan ; Herman Tse ; HONGLIN CHEN ; Candy Choi-Yi Lau ; Jian-Piao Cai ; Alan Ka-Lun Tsang ; XINCAI XIAO ; Kelvin Kai-Wang To ; Susanna Kar-Pui Lau ; Patrick Chiu-Yat Woo ; Bo-Jiang Zheng ; MING WANG ; Kwok-Yung YuenSource :
- The Journal of infection [ 0163-4453 ] ; 2013.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Objectives: A severe acute respiratory syndrome (SARS)-like disease due to a novel betacoronavirus, human coronavirus EMC (HCoV-EMC), has emerged recently. HCoV-EMC is phylogenetically closely related to Tylonycteris-bat-coronavirus-HKU4 and Pipistrellus-bat-coronavirus-HKU5 in Hong Kong. We conducted a seroprevalence study on archived sera from 94 game-food animal handlers at a wild life market, 28 SARS patients, and 152 healthy blood donors in Southern China to assess the zoonotic potential and evidence for intrusion of HCoV-EMC and related viruses into humans. Methods: Anti-HCoV-EMC and anti-SARS-CoV antibodies were detected using screening indirect immunofluorescence (IF) and confirmatory neutralizing antibody tests. Results: Two (2.1%) animal handlers had IF antibody titer of ≥1:20 against both HCoV-EMC and SARS-CoV with neutralizing antibody titer of <1:10. No blood donor had antibody against either virus. Surprisingly, 17/28 (60.7%) of SARS patients had significant IF antibody titers with 7/28 (25%) having anti-HCoV-EMC neutralizing antibodies at low titers which significantly correlated with that of HCoV-OC43. Bioinformatics analysis demonstrated a significant B-cell epitope overlapping the heptad repeat-2 region of Spike protein. Virulence of SARS-CoV over other betacoronaviruses may boost cross-reactive neutralizing antibodies against other betacoronaviruses. Conclusions: Convalescent SARS sera may contain cross-reactive antibodies against other betacoronaviruses and confound seroprevalence study for HCoV-EMC.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 13-0231386 INIST |
|---|---|
| ET : | Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests |
| AU : | CHAN (Kwok-Hung); CHAN (Jasper Fuk-Woo); TSE (Herman); HONGLIN CHEN; LAU (Candy Choi-Yi); CAI (Jian-Piao); TSANG (Alan Ka-Lun); XINCAI XIAO; TO (Kelvin Kai-Wang); LAU (Susanna Kar-Pui); WOO (Patrick Chiu-Yat); ZHENG (Bo-Jiang); MING WANG; YUEN (Kwok-Yung) |
| AF : | Department of Microbiology, Queen Mary Hospital, The University of Hong Kong/Hong-Kong (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 9 aut., 10 aut., 11 aut., 12 aut., 14 aut.); State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong/Hong-Kong (3 aut., 4 aut., 9 aut., 10 aut., 11 aut., 12 aut., 14 aut.); Research Centre of Infection and Immunology, The University of Hong Kong/Hong-Kong (3 aut., 4 aut., 9 aut., 10 aut., 11 aut., 12 aut., 14 aut.); Carol Yu Centre for Infection, The University of Hong Kong/Hong-Kong (3 aut., 4 aut., 9 aut., 10 aut., 11 aut., 12 aut., 14 aut.); Guangzhou Center for Disease Control and Prevention/Guangzhou/Chine (8 aut., 13 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | The Journal of infection; ISSN 0163-4453; Coden JINFD2; Pays-Bas; Da. 2013; Vol. 67; No. 2; Pp. 130-140; Bibl. 63 ref. |
| LA : | Anglais |
| EA : | Objectives: A severe acute respiratory syndrome (SARS)-like disease due to a novel betacoronavirus, human coronavirus EMC (HCoV-EMC), has emerged recently. HCoV-EMC is phylogenetically closely related to Tylonycteris-bat-coronavirus-HKU4 and Pipistrellus-bat-coronavirus-HKU5 in Hong Kong. We conducted a seroprevalence study on archived sera from 94 game-food animal handlers at a wild life market, 28 SARS patients, and 152 healthy blood donors in Southern China to assess the zoonotic potential and evidence for intrusion of HCoV-EMC and related viruses into humans. Methods: Anti-HCoV-EMC and anti-SARS-CoV antibodies were detected using screening indirect immunofluorescence (IF) and confirmatory neutralizing antibody tests. Results: Two (2.1%) animal handlers had IF antibody titer of ≥1:20 against both HCoV-EMC and SARS-CoV with neutralizing antibody titer of <1:10. No blood donor had antibody against either virus. Surprisingly, 17/28 (60.7%) of SARS patients had significant IF antibody titers with 7/28 (25%) having anti-HCoV-EMC neutralizing antibodies at low titers which significantly correlated with that of HCoV-OC43. Bioinformatics analysis demonstrated a significant B-cell epitope overlapping the heptad repeat-2 region of Spike protein. Virulence of SARS-CoV over other betacoronaviruses may boost cross-reactive neutralizing antibodies against other betacoronaviruses. Conclusions: Convalescent SARS sera may contain cross-reactive antibodies against other betacoronaviruses and confound seroprevalence study for HCoV-EMC. |
| CC : | 002B01; 002B05C02C |
| FD : | Syndrome respiratoire aigu sévère; Réaction croisée; Anticorps; Sérum; Homme; Coronavirus; Neutralisation |
| FG : | Virose; Infection; Coronaviridae; Nidovirales; Virus; Pathologie de l'appareil respiratoire; Pathologie des poumons |
| ED : | Severe acute respiratory syndrome; Cross reaction; Antibody; Serum; Human; Coronavirus; Neutralization |
| EG : | Viral disease; Infection; Coronaviridae; Nidovirales; Virus; Respiratory disease; Lung disease |
| SD : | Síndrome respiratorio agudo severo; Reacción cruzada; Anticuerpo; Suero; Hombre; Coronavirus; Neutralización |
| LO : | INIST-18250.354000503080070050 |
| ID : | 13-0231386 |
Links to Exploration step
Pascal:13-0231386Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests</title><author><name sortKey="Chan, Kwok Hung" sort="Chan, Kwok Hung" uniqKey="Chan K" first="Kwok-Hung" last="Chan">Kwok-Hung Chan</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Chan, Jasper Fuk Woo" sort="Chan, Jasper Fuk Woo" uniqKey="Chan J" first="Jasper Fuk-Woo" last="Chan">Jasper Fuk-Woo Chan</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Tse, Herman" sort="Tse, Herman" uniqKey="Tse H" first="Herman" last="Tse">Herman Tse</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Research Centre of Infection and Immunology, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Carol Yu Centre for Infection, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Honglin Chen" sort="Honglin Chen" uniqKey="Honglin Chen" last="Honglin Chen">HONGLIN CHEN</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Research Centre of Infection and Immunology, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Carol Yu Centre for Infection, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lau, Candy Choi Yi" sort="Lau, Candy Choi Yi" uniqKey="Lau C" first="Candy Choi-Yi" last="Lau">Candy Choi-Yi Lau</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Cai, Jian Piao" sort="Cai, Jian Piao" uniqKey="Cai J" first="Jian-Piao" last="Cai">Jian-Piao Cai</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Tsang, Alan Ka Lun" sort="Tsang, Alan Ka Lun" uniqKey="Tsang A" first="Alan Ka-Lun" last="Tsang">Alan Ka-Lun Tsang</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Xincai Xiao" sort="Xincai Xiao" uniqKey="Xincai Xiao" last="Xincai Xiao">XINCAI XIAO</name><affiliation><inist:fA14 i1="05"><s1>Guangzhou Center for Disease Control and Prevention</s1><s2>Guangzhou</s2><s3>CHN</s3><sZ>8 aut.</sZ><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="To, Kelvin Kai Wang" sort="To, Kelvin Kai Wang" uniqKey="To K" first="Kelvin Kai-Wang" last="To">Kelvin Kai-Wang To</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Research Centre of Infection and Immunology, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Carol Yu Centre for Infection, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lau, Susanna Kar Pui" sort="Lau, Susanna Kar Pui" uniqKey="Lau S" first="Susanna Kar-Pui" last="Lau">Susanna Kar-Pui Lau</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Research Centre of Infection and Immunology, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Carol Yu Centre for Infection, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Woo, Patrick Chiu Yat" sort="Woo, Patrick Chiu Yat" uniqKey="Woo P" first="Patrick Chiu-Yat" last="Woo">Patrick Chiu-Yat Woo</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Research Centre of Infection and Immunology, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Carol Yu Centre for Infection, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Zheng, Bo Jiang" sort="Zheng, Bo Jiang" uniqKey="Zheng B" first="Bo-Jiang" last="Zheng">Bo-Jiang Zheng</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Research Centre of Infection and Immunology, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Carol Yu Centre for Infection, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ming Wang" sort="Ming Wang" uniqKey="Ming Wang" last="Ming Wang">MING WANG</name><affiliation><inist:fA14 i1="05"><s1>Guangzhou Center for Disease Control and Prevention</s1><s2>Guangzhou</s2><s3>CHN</s3><sZ>8 aut.</sZ><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Yuen, Kwok Yung" sort="Yuen, Kwok Yung" uniqKey="Yuen K" first="Kwok-Yung" last="Yuen">Kwok-Yung Yuen</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Research Centre of Infection and Immunology, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Carol Yu Centre for Infection, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">13-0231386</idno><date when="2013">2013</date><idno type="stanalyst">PASCAL 13-0231386 INIST</idno><idno type="RBID">Pascal:13-0231386</idno><idno type="wicri:Area/PascalFrancis/Corpus">000024</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests</title><author><name sortKey="Chan, Kwok Hung" sort="Chan, Kwok Hung" uniqKey="Chan K" first="Kwok-Hung" last="Chan">Kwok-Hung Chan</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Chan, Jasper Fuk Woo" sort="Chan, Jasper Fuk Woo" uniqKey="Chan J" first="Jasper Fuk-Woo" last="Chan">Jasper Fuk-Woo Chan</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Tse, Herman" sort="Tse, Herman" uniqKey="Tse H" first="Herman" last="Tse">Herman Tse</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Research Centre of Infection and Immunology, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Carol Yu Centre for Infection, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Honglin Chen" sort="Honglin Chen" uniqKey="Honglin Chen" last="Honglin Chen">HONGLIN CHEN</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Research Centre of Infection and Immunology, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Carol Yu Centre for Infection, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lau, Candy Choi Yi" sort="Lau, Candy Choi Yi" uniqKey="Lau C" first="Candy Choi-Yi" last="Lau">Candy Choi-Yi Lau</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Cai, Jian Piao" sort="Cai, Jian Piao" uniqKey="Cai J" first="Jian-Piao" last="Cai">Jian-Piao Cai</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Tsang, Alan Ka Lun" sort="Tsang, Alan Ka Lun" uniqKey="Tsang A" first="Alan Ka-Lun" last="Tsang">Alan Ka-Lun Tsang</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Xincai Xiao" sort="Xincai Xiao" uniqKey="Xincai Xiao" last="Xincai Xiao">XINCAI XIAO</name><affiliation><inist:fA14 i1="05"><s1>Guangzhou Center for Disease Control and Prevention</s1><s2>Guangzhou</s2><s3>CHN</s3><sZ>8 aut.</sZ><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="To, Kelvin Kai Wang" sort="To, Kelvin Kai Wang" uniqKey="To K" first="Kelvin Kai-Wang" last="To">Kelvin Kai-Wang To</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Research Centre of Infection and Immunology, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Carol Yu Centre for Infection, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lau, Susanna Kar Pui" sort="Lau, Susanna Kar Pui" uniqKey="Lau S" first="Susanna Kar-Pui" last="Lau">Susanna Kar-Pui Lau</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Research Centre of Infection and Immunology, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Carol Yu Centre for Infection, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Woo, Patrick Chiu Yat" sort="Woo, Patrick Chiu Yat" uniqKey="Woo P" first="Patrick Chiu-Yat" last="Woo">Patrick Chiu-Yat Woo</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Research Centre of Infection and Immunology, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Carol Yu Centre for Infection, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Zheng, Bo Jiang" sort="Zheng, Bo Jiang" uniqKey="Zheng B" first="Bo-Jiang" last="Zheng">Bo-Jiang Zheng</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Research Centre of Infection and Immunology, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Carol Yu Centre for Infection, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ming Wang" sort="Ming Wang" uniqKey="Ming Wang" last="Ming Wang">MING WANG</name><affiliation><inist:fA14 i1="05"><s1>Guangzhou Center for Disease Control and Prevention</s1><s2>Guangzhou</s2><s3>CHN</s3><sZ>8 aut.</sZ><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Yuen, Kwok Yung" sort="Yuen, Kwok Yung" uniqKey="Yuen K" first="Kwok-Yung" last="Yuen">Kwok-Yung Yuen</name><affiliation><inist:fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Research Centre of Infection and Immunology, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>Carol Yu Centre for Infection, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">The Journal of infection</title><title level="j" type="abbreviated">J. infect.</title><idno type="ISSN">0163-4453</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">The Journal of infection</title><title level="j" type="abbreviated">J. infect.</title><idno type="ISSN">0163-4453</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibody</term><term>Coronavirus</term><term>Cross reaction</term><term>Human</term><term>Neutralization</term><term>Serum</term><term>Severe acute respiratory syndrome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term><term>Réaction croisée</term><term>Anticorps</term><term>Sérum</term><term>Homme</term><term>Coronavirus</term><term>Neutralisation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objectives: A severe acute respiratory syndrome (SARS)-like disease due to a novel betacoronavirus, human coronavirus EMC (HCoV-EMC), has emerged recently. HCoV-EMC is phylogenetically closely related to Tylonycteris-bat-coronavirus-HKU4 and Pipistrellus-bat-coronavirus-HKU5 in Hong Kong. We conducted a seroprevalence study on archived sera from 94 game-food animal handlers at a wild life market, 28 SARS patients, and 152 healthy blood donors in Southern China to assess the zoonotic potential and evidence for intrusion of HCoV-EMC and related viruses into humans. Methods: Anti-HCoV-EMC and anti-SARS-CoV antibodies were detected using screening indirect immunofluorescence (IF) and confirmatory neutralizing antibody tests. Results: Two (2.1%) animal handlers had IF antibody titer of ≥1:20 against both HCoV-EMC and SARS-CoV with neutralizing antibody titer of <1:10. No blood donor had antibody against either virus. Surprisingly, 17/28 (60.7%) of SARS patients had significant IF antibody titers with 7/28 (25%) having anti-HCoV-EMC neutralizing antibodies at low titers which significantly correlated with that of HCoV-OC43. Bioinformatics analysis demonstrated a significant B-cell epitope overlapping the heptad repeat-2 region of Spike protein. Virulence of SARS-CoV over other betacoronaviruses may boost cross-reactive neutralizing antibodies against other betacoronaviruses. Conclusions: Convalescent SARS sera may contain cross-reactive antibodies against other betacoronaviruses and confound seroprevalence study for HCoV-EMC.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0163-4453</s0></fA01><fA02 i1="01"><s0>JINFD2</s0></fA02><fA03 i2="1"><s0>J. infect.</s0></fA03><fA05><s2>67</s2></fA05><fA06><s2>2</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests</s1></fA08><fA11 i1="01" i2="1"><s1>CHAN (Kwok-Hung)</s1></fA11><fA11 i1="02" i2="1"><s1>CHAN (Jasper Fuk-Woo)</s1></fA11><fA11 i1="03" i2="1"><s1>TSE (Herman)</s1></fA11><fA11 i1="04" i2="1"><s1>HONGLIN CHEN</s1></fA11><fA11 i1="05" i2="1"><s1>LAU (Candy Choi-Yi)</s1></fA11><fA11 i1="06" i2="1"><s1>CAI (Jian-Piao)</s1></fA11><fA11 i1="07" i2="1"><s1>TSANG (Alan Ka-Lun)</s1></fA11><fA11 i1="08" i2="1"><s1>XINCAI XIAO</s1></fA11><fA11 i1="09" i2="1"><s1>TO (Kelvin Kai-Wang)</s1></fA11><fA11 i1="10" i2="1"><s1>LAU (Susanna Kar-Pui)</s1></fA11><fA11 i1="11" i2="1"><s1>WOO (Patrick Chiu-Yat)</s1></fA11><fA11 i1="12" i2="1"><s1>ZHENG (Bo-Jiang)</s1></fA11><fA11 i1="13" i2="1"><s1>MING WANG</s1></fA11><fA11 i1="14" i2="1"><s1>YUEN (Kwok-Yung)</s1></fA11><fA14 i1="01"><s1>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong</s1><s3>HKG</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></fA14><fA14 i1="02"><s1>State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></fA14><fA14 i1="03"><s1>Research Centre of Infection and Immunology, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></fA14><fA14 i1="04"><s1>Carol Yu Centre for Infection, The University of Hong Kong</s1><s3>HKG</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>14 aut.</sZ></fA14><fA14 i1="05"><s1>Guangzhou Center for Disease Control and Prevention</s1><s2>Guangzhou</s2><s3>CHN</s3><sZ>8 aut.</sZ><sZ>13 aut.</sZ></fA14><fA20><s1>130-140</s1></fA20><fA21><s1>2013</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>18250</s2><s5>354000503080070050</s5></fA43><fA44><s0>0000</s0><s1>© 2013 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>63 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>13-0231386</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>The Journal of infection</s0></fA64><fA66 i1="01"><s0>NLD</s0></fA66><fC01 i1="01" l="ENG"><s0>Objectives: A severe acute respiratory syndrome (SARS)-like disease due to a novel betacoronavirus, human coronavirus EMC (HCoV-EMC), has emerged recently. HCoV-EMC is phylogenetically closely related to Tylonycteris-bat-coronavirus-HKU4 and Pipistrellus-bat-coronavirus-HKU5 in Hong Kong. We conducted a seroprevalence study on archived sera from 94 game-food animal handlers at a wild life market, 28 SARS patients, and 152 healthy blood donors in Southern China to assess the zoonotic potential and evidence for intrusion of HCoV-EMC and related viruses into humans. Methods: Anti-HCoV-EMC and anti-SARS-CoV antibodies were detected using screening indirect immunofluorescence (IF) and confirmatory neutralizing antibody tests. Results: Two (2.1%) animal handlers had IF antibody titer of ≥1:20 against both HCoV-EMC and SARS-CoV with neutralizing antibody titer of <1:10. No blood donor had antibody against either virus. Surprisingly, 17/28 (60.7%) of SARS patients had significant IF antibody titers with 7/28 (25%) having anti-HCoV-EMC neutralizing antibodies at low titers which significantly correlated with that of HCoV-OC43. Bioinformatics analysis demonstrated a significant B-cell epitope overlapping the heptad repeat-2 region of Spike protein. Virulence of SARS-CoV over other betacoronaviruses may boost cross-reactive neutralizing antibodies against other betacoronaviruses. Conclusions: Convalescent SARS sera may contain cross-reactive antibodies against other betacoronaviruses and confound seroprevalence study for HCoV-EMC.</s0></fC01><fC02 i1="01" i2="X"><s0>002B01</s0></fC02><fC02 i1="02" i2="X"><s0>002B05C02C</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Réaction croisée</s0><s5>07</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Cross reaction</s0><s5>07</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Reacción cruzada</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Anticorps</s0><s5>08</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Antibody</s0><s5>08</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Anticuerpo</s0><s5>08</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Sérum</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Serum</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Suero</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Human</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Coronavirus</s0><s2>NW</s2><s5>11</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Coronavirus</s0><s2>NW</s2><s5>11</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Coronavirus</s0><s2>NW</s2><s5>11</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Neutralisation</s0><s5>13</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Neutralization</s0><s5>13</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Neutralización</s0><s5>13</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Pathologie de l'appareil respiratoire</s0><s5>37</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Respiratory disease</s0><s5>37</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0><s5>37</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Pathologie des poumons</s0><s5>38</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Lung disease</s0><s5>38</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Pulmón patología</s0><s5>38</s5></fC07><fN21><s1>217</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 13-0231386 INIST</NO><ET>Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests</ET><AU>CHAN (Kwok-Hung); CHAN (Jasper Fuk-Woo); TSE (Herman); HONGLIN CHEN; LAU (Candy Choi-Yi); CAI (Jian-Piao); TSANG (Alan Ka-Lun); XINCAI XIAO; TO (Kelvin Kai-Wang); LAU (Susanna Kar-Pui); WOO (Patrick Chiu-Yat); ZHENG (Bo-Jiang); MING WANG; YUEN (Kwok-Yung)</AU><AF>Department of Microbiology, Queen Mary Hospital, The University of Hong Kong/Hong-Kong (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 9 aut., 10 aut., 11 aut., 12 aut., 14 aut.); State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong/Hong-Kong (3 aut., 4 aut., 9 aut., 10 aut., 11 aut., 12 aut., 14 aut.); Research Centre of Infection and Immunology, The University of Hong Kong/Hong-Kong (3 aut., 4 aut., 9 aut., 10 aut., 11 aut., 12 aut., 14 aut.); Carol Yu Centre for Infection, The University of Hong Kong/Hong-Kong (3 aut., 4 aut., 9 aut., 10 aut., 11 aut., 12 aut., 14 aut.); Guangzhou Center for Disease Control and Prevention/Guangzhou/Chine (8 aut., 13 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>The Journal of infection; ISSN 0163-4453; Coden JINFD2; Pays-Bas; Da. 2013; Vol. 67; No. 2; Pp. 130-140; Bibl. 63 ref.</SO><LA>Anglais</LA><EA>Objectives: A severe acute respiratory syndrome (SARS)-like disease due to a novel betacoronavirus, human coronavirus EMC (HCoV-EMC), has emerged recently. HCoV-EMC is phylogenetically closely related to Tylonycteris-bat-coronavirus-HKU4 and Pipistrellus-bat-coronavirus-HKU5 in Hong Kong. We conducted a seroprevalence study on archived sera from 94 game-food animal handlers at a wild life market, 28 SARS patients, and 152 healthy blood donors in Southern China to assess the zoonotic potential and evidence for intrusion of HCoV-EMC and related viruses into humans. Methods: Anti-HCoV-EMC and anti-SARS-CoV antibodies were detected using screening indirect immunofluorescence (IF) and confirmatory neutralizing antibody tests. Results: Two (2.1%) animal handlers had IF antibody titer of ≥1:20 against both HCoV-EMC and SARS-CoV with neutralizing antibody titer of <1:10. No blood donor had antibody against either virus. Surprisingly, 17/28 (60.7%) of SARS patients had significant IF antibody titers with 7/28 (25%) having anti-HCoV-EMC neutralizing antibodies at low titers which significantly correlated with that of HCoV-OC43. Bioinformatics analysis demonstrated a significant B-cell epitope overlapping the heptad repeat-2 region of Spike protein. Virulence of SARS-CoV over other betacoronaviruses may boost cross-reactive neutralizing antibodies against other betacoronaviruses. Conclusions: Convalescent SARS sera may contain cross-reactive antibodies against other betacoronaviruses and confound seroprevalence study for HCoV-EMC.</EA><CC>002B01; 002B05C02C</CC><FD>Syndrome respiratoire aigu sévère; Réaction croisée; Anticorps; Sérum; Homme; Coronavirus; Neutralisation</FD><FG>Virose; Infection; Coronaviridae; Nidovirales; Virus; Pathologie de l'appareil respiratoire; Pathologie des poumons</FG><ED>Severe acute respiratory syndrome; Cross reaction; Antibody; Serum; Human; Coronavirus; Neutralization</ED><EG>Viral disease; Infection; Coronaviridae; Nidovirales; Virus; Respiratory disease; Lung disease</EG><SD>Síndrome respiratorio agudo severo; Reacción cruzada; Anticuerpo; Suero; Hombre; Coronavirus; Neutralización</SD><LO>INIST-18250.354000503080070050</LO><ID>13-0231386</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000024 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000024 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:13-0231386
|texte= Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests
}}
| This area was generated with Dilib version V0.6.33. |  |